Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

Name: Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
Published: 2026
License: Public Domain

Novo Nordisk A/S · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

diabetes-mellitus type-2

diabetes mellitus, type 2, observational

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

Related documents